Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial
Department of Pediatrics
Aged; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Cross-Over Studies; Female; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Thiophenes; Thrombolytic Therapy; Ticlopidine; derivatives; Treatment Outcome
Hematology | Oncology | Pediatrics
BACKGROUND: The increasing use of higher-than-approved doses of clopidogrel in clinical practice is based in part on the desire for greater levels of inhibition of platelet aggregation (IPA). Prasugrel is a new thienopyridine that is more potent than standard-dose clopidogrel in healthy subjects and patients with stable coronary artery disease. The relative antiplatelet effects of prasugrel versus high-dose clopidogrel in percutaneous coronary intervention patients are unknown.
METHODS AND RESULTS: Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 (PRINCIPLE-TIMI 44) was a randomized, double-blind, 2-phase crossover study of prasugrel compared with high-dose clopidogrel in patients undergoing cardiac catheterization for planned percutaneous coronary intervention. The primary end point of the loading-dose phase (prasugrel 60 mg versus clopidogrel 600 mg) was IPA with 20 mumol/L ADP at 6 hours. Patients with percutaneous coronary intervention entered the maintenance-dose phase, a 28-day crossover comparison of prasugrel 10 mg/d versus clopidogrel 150 mg/d with a primary end point of IPA after 14 days of either drug. In this study, 201 subjects were randomized. IPA at 6 hours was significantly higher in subjects receiving prasugrel (mean+/-SD, 74.8+/-13.0%) compared with clopidogrel (31.8+/-21.1%; Pandlt;0.0001). During the maintenance-dose phase, IPA with 20 mumol/L ADP was higher in subjects receiving prasugrel (61.3+/-17.8%) compared with clopidogrel (46.1+/-21.3%; Pandlt;0.0001). Results were consistent across all key secondary end points; significant differences emerged by 30 minutes and persisted across all time points.
CONCLUSIONS: Among patients undergoing cardiac catheterization with planned percutaneous coronary intervention, loading with 60 mg prasugrel resulted in greater platelet inhibition than a 600-mg clopidogrel loading dose. Maintenance therapy with prasugrel 10 mg/d resulted in a greater antiplatelet effect than 150 mg/d clopidogrel.
DOI of Published Version
Circulation. 2007 Dec 18;116(25):2923-32. Epub 2007 Dec 3. doi: 10.1161/CIRCULATIONAHA.107.740324
Wiviott, Stephen D.; Trenk, Dietmar; Frelinger, Andrew L. III; O'Donoghue, Michelle; Neumann, Franz-Josef; Michelson, Alan D.; Angiolillo, Dominick J.; Hod, Hanoch; Montalescot, Gilles; Miller, Debra L.; Jakubowski, Joseph A.; Cairns, Richard; Murphy, Sabina A.; McCabe, Carolyn H.; Antman, Elliott M.; and Braunwald, Eugene, "Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial" (2007). Hematology/Oncology. 90.